Skip to main content
. 2020 Nov 6;124(3):587–594. doi: 10.1038/s41416-020-01140-9

Fig. 3. Primary tumour location and survival in the RAS wild-type per-protocol population.

Fig. 3

Left-sided tumours (N = 273): a progression-free survival, b overall survival; right-sided tumours (N = 75): c progression-free survival, d overall survival. Bev bevacizumab, Cet cetuximab.